Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SPINOFF FROM NOVARTIS AG'S ACQUISITION OF AVIDITY BIOSCIENCES ADVANCES PRECISION CARDIOLOGY PROGRAMS USING TARGETED RNA DELIVERY PLATFORM LEAD CANDIDATES ATR 1072 AND ATR 1086 EXPECTED TO ENTER CLINICAL TRIALS FOR PRKAG2 SYNDROME AND PLN CARDIOMYOPATHY, RESPECTIVELY SAN DIEGO, FEB. 27, 2026 /PRNEWSWIRE/ -- ATRIUM THERAPEUTICS, INC. (NASDAQ: RNA) LAUNCHED TODAY AS A NEWLY INDEPENDENT, PUBLICLY TRADED COMPANY DEDICATED TO DELIVERING RNA THERAPEUTICS DIRECTLY TO THE HEART TO TRANSFORM CARE FOR PEOPLE LIVING WITH RARE, LIFE-THREATENING GENETIC CARDIOMYOPATHIES. ATRIUM THERAPEUTICS WAS ESTABLISHED IN CONNECTION WITH AVIDITY BIOSCIENCES, INC.'S ACQUISITION BY NOVARTIS AG.

ATRIUM THERAPEUTICS LAUNCHES WITH APPROXIMATELY $270 MILLION TO ADVANCE NOVEL RNA MEDICINES FOR RARE GENETIC CARDIOMYOPATHIES

SAN DIEGO, FEB. 26, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS) TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT THE COMPANY WILL BE PRESENTING ONE ORAL AND SIX POSTER PRESENTATIONS AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE, BEING HELD MARCH 8-11, 2026, IN ORLANDO, FLORIDA. 2026 MDA CLINICAL & SCIENTIFIC CONGRESS PRESENTATIONS ORAL PRESENTATION: DEL-ZOTA TREATMENT IS ASSOCIATED WITH NEAR NORMALIZATION OF CK LEVELS AND IMPROVEMENTS IN KEY FUNCTIONAL OUTCOMES AT 1 YEAR IN PARTICIPANTS WITH DMD44 (MARCH 11, 2026: 12:30 P.M.

AVIDITY BIOSCIENCES ANNOUNCES MULTIPLE UPCOMING PRESENTATIONS AT 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE

SAN DIEGO, FEB. 23, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES ("AOCS") TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT IT INTENDS TO CONVENE ITS UPCOMING SPECIAL MEETING OF STOCKHOLDERS (THE "SPECIAL MEETING") SCHEDULED FOR FEBRUARY 23, 2026, AT 10:00 A.M., EASTERN TIME, AND THEN IMMEDIATELY ADJOURN PROCEEDINGS, WITHOUT CONDUCTING ANY OTHER BUSINESS.

AVIDITY BIOSCIENCES ANNOUNCES INTENTION TO ADJOURN AND RECONVENE SPECIAL MEETING OF STOCKHOLDERS

DEL-DESIRAN EFFECTIVELY DELIVERED SIRNA TO MUSCLE, RESULTING IN APPROXIMATELY 40% MEAN REDUCTION IN DMPK MRNA AND AMELIORATION OF MISSPLICING TREATMENT DEMONSTRATED IMPROVEMENTS IN MULTIPLE MEASURES INCLUDING MYOTONIA, MUSCLE FUNCTION AND STRENGTH, MOBILITY AND PATIENT-REPORTED OUTCOMES DEL-DESIRAN SHOWED ACCEPTABLE SAFETY AND TOLERABILITY WITH MOST ADVERSE EVENTS MILD OR MODERATE SAN DIEGO, FEB. 18, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. (NASDAQ:RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES (AOCS), TODAY ANNOUNCED THAT THE FINAL RESULTS FROM THE COMPLETED PHASE 1/2 MARINA TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) IN PEOPLE LIVING WITH MYOTONIC DYSTROPHY TYPE 1 (DM1) WILL BE PUBLISHED IN THE FEBRUARY 19 ISSUE OF THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM). THE MANUSCRIPT IS TITLED "AN ANTIBODY OLIGONUCLEOTIDE CONJUGATE FOR MYOTONIC DYSTROPHY TYPE 1.

THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS FROM PHASE 1/2 MARINA TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1

SAN DIEGO, FEB. 2, 2026 /PRNEWSWIRE/ -- AVIDITY BIOSCIENCES, INC. ("AVIDITY") (NASDAQ: RNA), A BIOPHARMACEUTICAL COMPANY COMMITTED TO DELIVERING A NEW CLASS OF RNA THERAPEUTICS CALLED ANTIBODY OLIGONUCLEOTIDE CONJUGATES ("AOCS") TO PROFOUNDLY IMPROVE PEOPLE'S LIVES, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DESIGNATED THE CLOSE OF BUSINESS, EASTERN TIME, ON FEBRUARY 12, 2026 AS THE RECORD DATE (THE "RECORD DATE") FOR THE PRO RATA DISTRIBUTION OF ALL OF THE ISSUED AND OUTSTANDING SHARES OF COMMON STOCK OF ATRIUM THERAPEUTICS, INC. ("SPINCO") TO HOLDERS OF AVIDITY COMMON STOCK ON THE RECORD DATE IN CONNECTION WITH THE PREVIOUSLY ANNOUNCED PROPOSED ACQUISITION OF AVIDITY BY NOVARTIS AG (THE "MERGER") AND THE SEPARATION OF AVIDITY'S EARLY-STAGE PRECISION CARDIOLOGY PROGRAMS INTO SPINCO (THE "SPIN-OFF"). EACH SUCH HOLDER WILL RECEIVE ONE SHARE OF SPINCO COMMON STOCK FOR EVERY TEN SHARES OF AVIDITY COMMON STOCK HELD ON THE RECORD DATE.

AVIDITY BIOSCIENCES ANNOUNCES EXPECTED RECORD DATE FOR SPIN-OFF

BOULDER, CO / ACCESS NEWSWIRE / JANUARY 28, 2026 / SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA), A GLOBAL HEALTHCARE LEADER DEVELOPING AND PRODUCING PATENTED MICROCYN TECHNOLOGY BASED STABILIZED HYPOCHLOROUS ACID (HOCL) PRODUCTS FOR A WIDE RANGE OF APPLICATIONS, INCLUDING WOUND CARE, EYE CARE, DERMATOLOGICAL CONDITIONS, PODIATRY, AND ANIMAL HEALTH CARE, TODAY ANNOUNCED THE APPOINTMENT OF VANESSA JACOBY, CHIEF BUSINESS AND FINANCIAL OFFICER OF QUANTA THERAPEUTICS, INC., TO ITS BOARD OF DIRECTORS AND TO SERVE AS CHAIR OF ITS AUDIT COMMITTEE. SONOMA ALSO ANNOUNCED THE RETIREMENT OF ITS LONGTIME DIRECTOR, DR. JAY BIRNBAUM.

Avidity Biosciences, Inc.

RNA

Price

Financial Reports

No items found.

Press Releases

Avidity Biosciences, Inc.

RNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RNA